Review
doi: 10.1111/j.1076-7460.2006.05083.x.
The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions
Affiliations
- PMID: 16849895
- DOI: 10.1111/j.1076-7460.2006.05083.x
Item in Clipboard
Review
The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions
Am J Geriatr Cardiol.
2006 Jul-Aug.
No abstract available
Similar articles
-
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].J Pharm Belg. 2005;60(3):89-91. J Pharm Belg. 2005. PMID: 16252510 Review. French.
-
[Endocannabinoid and endocannabinoid receptor antagonists].Med Monatsschr Pharm. 2005 Feb;28(2):40-3. Med Monatsschr Pharm. 2005. PMID: 15727333 Review. German. No abstract available.
-
[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].Dtsch Med Wochenschr. 2005 Mar 24;130(12):665-8. doi: 10.1055/s-2005-865077. Dtsch Med Wochenschr. 2005. PMID: 15776349 German.
-
[Selective cannabinoid receptor antagonists].Pharm Unserer Zeit. 2006;35(6):512-20. doi: 10.1002/pauz.200600197. Pharm Unserer Zeit. 2006. PMID: 17137082 Review. German. No abstract available.
-
Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.Pharmacol Rep. 2009 Jan-Feb;61(1):13-21. doi: 10.1016/s1734-1140(09)70003-9. Pharmacol Rep. 2009. PMID: 19307689 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources